Abstract:With the application of Mendelian randomization and co‐localization analysis methods, we found compelling indications for two proteins (LRP11 and ITIH1) and suggested indications for four proteins (PLCG1, ARHGAP25, CHGA, and MANBA), which might be promising targets for migraine treatment without obvious adverse consequences. Background Proteome‐wide Mendelian randomization studies have been increasingly utilized to identify potential drug targets for diseases. We aimed to identify potential therapeutic targets for migraine and its subtypes through the application of Mendelian randomization and co‐localization analysis methods. Methods We utilized cis‐protein quantitative trait loci data for 1378 plasma proteins available from two studies with 7213 individuals and 35,559 individuals, respectively. Summary data for migraine and its subtypes were obtained from a genetic study involving up to 1,339,303 individuals. Proteins that passed both the discovery and validation Mendelian randomization analysis, sensitivity analysis, heterogeneity test, and pleiotropy test, were associated with ≥2 outcomes, and received strong support from co‐localization analysis (PP.H4.abf ≥0.80) and were classified as tier 1 proteins. Results We identified three tier 1 proteins (LRP11, ITIH1, and ADGRF5), whose genes have not been previously identified as causal genes for migraine in genetic studies. LRP11 was significantly associated with the risk of any migraine (OR [odds ratio] = 0.968, 95% CI [confidence interval] = 0.955–0.981, p = 1.27 × 10−6) and significantly/suggestively associated with three migraine subtypes. ITIH1 was significantly associated with the risk of any migraine (OR = 1.044, 95% CI = 1.024–1.065, p = 1.08 × 10−5) and migraine with visual disturbances. ADGRF5 was significantly associated with the risk of any migraine (OR = 0.964, 95% CI = 0.946–0.982, p = 8.74 × 10−5) and suggestively associated with migraine with aura. The effects of LRP11 and ADGRF5 were further replicated using cerebrospinal fluid protein data. Apart from ADGRF5, there was no evidence of potential adverse consequences when modulating the plasma levels. We also identified another four proteins (PLCG1, ARHGAP25, CHGA, and MANBA) with no potential adverse consequences when modulating the plasma levels, and their genes were not reported by previous genetic studies. Conclusions We found compelling evidence for two proteins and suggestive evidence for four proteins that could be promising targets for migraine treatment without significant adverse consequences. The corresponding genes were not reported in previous genetic studies. Future studies are needed to confirm the causal role of these proteins and explore the underlying mechanisms.

The 1400 metabolite-mediated relationship between 91 inflammatory cytokines and migraine: An exploratory two-step Mendelian randomization study

Inflammo-immune perspective on the association of eight migraine risk factors with migraine: a multi-omics Mendelian randomization study

To analyze the relationship between gut microbiota, metabolites and migraine: a two-sample Mendelian randomization study

Causal relationship between primary headache mediated by circulating cytokines and cerebral cortex structure: a mediation Mendelian randomization study

Irritable Bowel Syndrome and Migraine: Evidence from Mendelian Randomization Analysis in the UK Biobank

Causal associations of immune cell phenotypes with migraine: A mendelian randomization study

Proteome-wide Mendelian randomization identified potential drug targets for migraine

Assessing the associations of 1,400 blood metabolites with major depressive disorder: a Mendelian randomization study

Exploring causal correlations between inflammatory cytokines and Ménière's disease: a Mendelian randomization

Mediators of the association between depression and migraine: a mendelian randomization study

Identifying novel proteins for migraine by integrating proteomes from blood and CSF with genome‐wide association data

The relationship between major depression and migraine: A bidirectional two-sample Mendelian randomization study

Genetically predicted circulating levels of cytokines and the risk of depression: a bidirectional Mendelian-randomization study

Migraine and gastroesophageal reflux disease: Disentangling the complex connection with depression as a mediator

Genetic causal relationship between immune diseases and migraine: a Mendelian randomization study

Causal relationships between immunophenotypes, plasma metabolites, and temporomandibular disorders based on Mendelian randomization

Causality between migraine and cardiovascular disease: a bidirectional Mendelian randomization study

Mendelian randomization study of lipid metabolism characteristics and migraine risk

Exploration of the causal associations between circulating inflammatory proteins, immune cells, and neuromyelitis optica spectrum disorder: a bidirectional Mendelian randomization study and mediation analysis

A multi-omics bidirectional mendelian randomization study and meta-analysis on the causal relationship between gut microbiota, inflammatory proteins, and fibromyalgia.

Causal relationship of inflammatory cytokines and serum metabolites in cerebral small vessel disease: a two‐step Mendelian randomization study